Vyome Holdings, Inc. (NASDAQ:HIND) Receives Average Recommendation of “Hold” from Brokerages

Vyome Holdings, Inc. (NASDAQ:HIND) has earned a consensus recommendation of “Hold” from the five research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $15.00.

HIND has been the topic of several recent research reports. Litchfield Hills Research started coverage on Vyome in a report on Monday, May 4th. They issued a “buy” rating on the stock. Weiss Ratings raised Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Finally, Zacks Research upgraded shares of Vyome to a “hold” rating in a research report on Wednesday, May 6th.

Vyome Stock Performance

Shares of HIND opened at $2.18 on Wednesday. The business’s fifty day moving average price is $2.18 and its two-hundred day moving average price is $2.43. The firm has a market capitalization of $15.30 million, a price-to-earnings ratio of -0.18 and a beta of 1.49. Vyome has a 52 week low of $1.75 and a 52 week high of $18.60.

Vyome (NASDAQ:HIND) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter. As a group, research analysts forecast that Vyome will post -0.6 EPS for the current year.

Hedge Funds Weigh In On Vyome

A hedge fund recently bought a new stake in Vyome stock. Millennium Management LLC bought a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned 0.80% of Vyome as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 22.06% of the company’s stock.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.